The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

about

When will resistance be futile?Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.

P2860

Q34715457-DF1676CE-AC37-4BFB-A46D-385D1360CDA9 Q35676486-18F5658C-56F8-429E-88DB-9614E624EDDA

P2860

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

Item

http://www.wikidata.org/entity/Q43089875

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

@en

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia

@nl

type

Item

label

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

@en

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia

@nl

prefLabel

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

@en

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia

@nl

P1476

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

@en

P2093

Eftihia Cocolakis

http://www.w3.org/2001/XMLSchema#string

Katherine L B Borden

http://www.w3.org/2001/XMLSchema#string

Sarit Assouline

http://www.w3.org/2001/XMLSchema#string

P2860

MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates

Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2

The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells

Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo

Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

P304

1161-1179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/CANCERS4041161

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258429975

http://www.w3.org/2001/XMLSchema#string

P698

24213503

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

3712735

http://www.w3.org/2001/XMLSchema#string

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

about

P2860

P2860

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932